Head to Head Review: Patheon NV (PTHN) & Teligent (TLGT)

Patheon NV (NASDAQ: PTHN) and Teligent (NASDAQ:TLGT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Patheon NV and Teligent, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Patheon NV 0 6 1 0 2.14
Teligent 0 1 2 0 2.67

Patheon NV currently has a consensus target price of $33.60, indicating a potential downside of 3.95%. Teligent has a consensus target price of $9.33, indicating a potential upside of 31.46%. Given Teligent’s stronger consensus rating and higher possible upside, analysts plainly believe Teligent is more favorable than Patheon NV.

Profitability

This table compares Patheon NV and Teligent’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Patheon NV 5.71% N/A 4.09%
Teligent -4.99% -6.32% -1.91%

Earnings and Valuation

This table compares Patheon NV and Teligent’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Patheon NV $1.93 billion 2.63 $352.50 million N/A N/A
Teligent $72.39 million 5.24 $6.48 million ($0.16) -44.38

Patheon NV has higher revenue and earnings than Teligent.

Insider and Institutional Ownership

66.0% of Teligent shares are held by institutional investors. 22.6% of Teligent shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Teligent beats Patheon NV on 7 of the 12 factors compared between the two stocks.

About Patheon NV

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

About Teligent

Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.

Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply